GlassScriptPhysician profile
Kimberly Sirk
NPI 1114281466
$15,762.97
in general payments reported to CMS, 2019-2025
34 companies · $2,264 in 2025
The $2,264 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,538 · 2022: $3,653 · 2023: $3,670 · 2024: $3,637 · 2025: $2,264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,204 · Education: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,204.32 |
| Education | $367.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,502.80 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,680.82 | 2021-2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $985.99 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Axsome Therapeutics, INC. | $964.59 | 2023-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $959.67 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Supernus Pharmaceuticals, INC. | $933.15 | 2021-2024 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $866.44 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $811.74 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $798.78 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Tris Pharma INC | $759.70 | 2021-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Corium, LLC | $595.99 | 2021-2025 | Azstarys, Azstarys |
| Lundbeck LLC | $567.46 | 2021-2025 | Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $524.91 | 2021-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $490.63 | 2021-2025 | Trintellix |
| Jazz Pharmaceuticals INC. | $434.18 | 2021-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $279.04 | 2023-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $199.61 | 2024-2025 | Cobenfy |
| Harmony Biosciences LLC | $179.50 | 2022-2025 | Wakix |
| Bausch Health US, LLC | $173.25 | 2021-2024 | Aplenzin, Wellbutrin |
| Merck Sharp & Dohme LLC | $159.18 | 2021-2023 | Belsomra |
| Sunovion Pharmaceuticals INC. | $153.25 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $148.40 | 2023-2025 | Lumryz |
| Ironshore Pharmaceuticals INC. | $138.92 | 2022-2024 | Jornay Pm |
| Almatica Pharma LLC | $111.04 | 2023-2025 | Loreev Xr |
| Noven Therapeutics, LLC | $65.01 | 2021-2025 | Xelstrym, Secuado |
| Collegium Pharmaceutical, INC. | $62.52 | 2025 | Jornay Pm |
| Owp Pharmaceuticals, INC. | $61.32 | 2022-2025 | Subvenite, Lamotrigine |
| Eisai INC. | $43.20 | 2021 | |
| Adlon Therapeutics L.P. | $26.31 | 2021 | |
| Neos Therapeutics, LP | $25.00 | 2024 | Adzenys Xr-Odt |
| Noven Pharmaceuticals, INC. | $17.26 | 2021 | |
| Braeburn INC. | $15.47 | 2024 | Brixadi |
| Indivior INC. | $15.01 | 2024 | Sublocade |
| Avanir Pharmaceuticals, INC. | $12.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Sirk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.